Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
51 hedge funds and large institutions have $30.4M invested in Neos Therapeutics, Inc in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 13 closing their positions.
3% more capital invested
Capital invested by funds: $29.4M → $30.4M (+$981K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 58 → 51 (-7)
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$431K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$319K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$144K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$113K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$81.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$759K |
| 2 |
Morgan Stanley
New York
|
-$674K |
| 3 |
Millennium Management
New York
|
-$654K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$629K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$387K |
NEOS Hedge Fund Activity: Q3 2019 in Review
51 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q3 2019, worth a combined $30.4M — up 3.3% from $29.4M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NEOS and 6 opened new positions — a net loss of 7 holders — while 18 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $431K. The largest seller was Stonepine Capital Management, cutting an estimated $759K.
- 51 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q3 2019, down from 58 in Q2 2019.
- Funds reported $30.4M of Neos Therapeutics, Inc stock for Q3 2019, up 3.3% quarter-over-quarter.
- 6 funds opened new Neos Therapeutics, Inc positions in Q3 2019 and 13 closed out, a net change of -7 holders.
- The largest Neos Therapeutics, Inc buyer in Q3 2019 was Renaissance Technologies, an estimated $431K added.
- The largest Neos Therapeutics, Inc seller in Q3 2019 was Stonepine Capital Management, an estimated $759K sold.
Based on aggregated 13F filings for Q3 2019.